L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of Parkinson's Disease (PD) therapy. Among the various pharmacological targets for novel therapeutic approaches, the serotonergic system represents a promising one. In experimental models of PD and in PD patients the development of abnormal involuntary movements (AIMs) and LIDs, respectively, is accompanied by the impairment of bidirectional synaptic plasticity in key structures such as striatum. Recently, it has been shown that the 5-HT1A/1B receptor agonist, eltoprazine, significantly decreased LIDs in experimental PD and human patients. Despite the fact that several papers have tested this and other serotonergic drugs, nothing is known about the electrophysiological consequences on this combined serotonin receptors modulation at striatal neurons. The present study demonstrates that activation of 5-HT1A/1B receptors reduces AlMs via the restoration of Long-Term Potentiation (LTP) and synaptic depotentiation in a sub-set of striatal spiny projection neurons (SPNs). This recovery is associated with the normalization of D1 receptor-dependent cAMP/PKA and ERK/mTORC signaling pathways, and the recovery of NMDA receptor subunits balance, indicating these events as key elements in AIMs induction. Moreover, we analyzed whether the manipulation of the serotonergic system might affect motor behavior and cognitive performances. We found that a defect in locomotor activity in parkinsonian and L-DOPA-treated rats was reversed by eltoprazine treatment. Conversely, the impairment in the striatal-dependent learning was found exacerbated in L-DOPA-treated rats and eltoprazine failed to recover it.

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia : Behavioral, molecular, and synaptic mechanisms / V. Ghiglieri, D. Mineo, A. Vannelli, F. Cacace, M. Mancini, V. Pendolino, F. Napolitano, A. di Maio, M. Mellone, J. Stanic, E. Tronci, C. Fidalgo, R. Stancampiano, M. Carta, P. Calabresi, F. Gardoni, A. Usiello, B. Picconi. - In: NEUROBIOLOGY OF DISEASE. - ISSN 0969-9961. - 86(2016 Feb), pp. 140-153. [10.1016/j.nbd.2015.11.022]

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia : Behavioral, molecular, and synaptic mechanisms

M. Mellone;J. Stanic;F. Gardoni;
2016

Abstract

L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of Parkinson's Disease (PD) therapy. Among the various pharmacological targets for novel therapeutic approaches, the serotonergic system represents a promising one. In experimental models of PD and in PD patients the development of abnormal involuntary movements (AIMs) and LIDs, respectively, is accompanied by the impairment of bidirectional synaptic plasticity in key structures such as striatum. Recently, it has been shown that the 5-HT1A/1B receptor agonist, eltoprazine, significantly decreased LIDs in experimental PD and human patients. Despite the fact that several papers have tested this and other serotonergic drugs, nothing is known about the electrophysiological consequences on this combined serotonin receptors modulation at striatal neurons. The present study demonstrates that activation of 5-HT1A/1B receptors reduces AlMs via the restoration of Long-Term Potentiation (LTP) and synaptic depotentiation in a sub-set of striatal spiny projection neurons (SPNs). This recovery is associated with the normalization of D1 receptor-dependent cAMP/PKA and ERK/mTORC signaling pathways, and the recovery of NMDA receptor subunits balance, indicating these events as key elements in AIMs induction. Moreover, we analyzed whether the manipulation of the serotonergic system might affect motor behavior and cognitive performances. We found that a defect in locomotor activity in parkinsonian and L-DOPA-treated rats was reversed by eltoprazine treatment. Conversely, the impairment in the striatal-dependent learning was found exacerbated in L-DOPA-treated rats and eltoprazine failed to recover it.
Bidirectional synaptic plasticity; Levodopa treatment; Parkinson's disease animal models; Serotonergic transmission
Settore BIO/14 - Farmacologia
feb-2016
27-nov-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0969996115301005-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.92 MB
Formato Adobe PDF
2.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/350116
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 46
social impact